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Introduction
Glutathione transferases (GSTs, EC 2.5.1.18) constitute an 
enzyme superfamily important in the medical and agricul-
tural sciences because they are involved in cellular detoxifi-
cation.1,2 GSTs confer protection to the cell against 
electrophilic metabolites, drugs, and toxic compounds. They 
do so by catalyzing the attack of the tripeptide glutathione 
(GSH) to the electrophilic center of such hydrophobic com-
pounds, thus facilitating the degradation and transport of the 
respective conjugates. GST isoenzymes differ in their tissue 
specificity, expression, and distribution. Within mammals, 
GSTs are subdivided into classes on the basis of their amino 
acid sequence, for example, α, µ, π, σ, θ, ζ, κ, and ω.3,4 Human 
cytosolic GSTs are found as homodimers,3,4 with each mono-
mer having an α/β domain that includes α1–α3 helices and a 
large α-helical domain composed of helices α4–α9. The for-
mer domain contains the GSH binding site (G-site) on top of 
the large α domain. A hydrophobic pocket (H-site) lies 
between the two domains in which the hydrophobic substrate 
binds and reacts with GSH.
Although GSTs’ detoxifying ability is a protective mecha-
nism of the cell against deleterious compounds, it hampers, on 
the other hand, the effectiveness of certain chemotherapeutic 
drugs against cancer cells. This phenomenon leads to 
chemotherapeutic-resistant tumor cells that no longer respond 
appropriately to the applied therapeutic protocol. A possible 
origin for this problem appears to be an elevated expression of 
total GST activity in malignant tissue.5,6 For the GSTP1-1 iso-
enzyme, GST-dependent prevention of anticancer drug-
induced apoptosis via direct interaction with signal 
transduction proteins has been suggested.7 Furthermore, 
homozygous hGSTA1*B breast cancer patients treated with 
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Abstract
Glutathione transferases (GSTs) are cell detoxifiers involved in multiple drug resistance (MDR), hampering the effectiveness 
of certain anticancer drugs. To our knowledge, this is the first report on well-defined synthetic xanthones as GST inhibitors. 
Screening 18 xanthones revealed three derivatives bearing a bromomethyl and a methyl group (7) or two bromomethyl 
groups (8) or an aldehyde group (17), with high inhibition potency (>85%), manifested by low IC50 values (7: 1.59 ± 0.25 µM, 
8: 5.30 ± 0.30 µM, and 17: 8.56 ± 0.14 µM) and a competitive modality of inhibition versus CDNB (Ki(7) = 0.76 ± 0.18 and 
Ki(17) = 1.69 ± 0.08 µM). Of them, derivative 17 readily inhibited hGSTA1-1 in colon cancer cell lysate (IC50 = 10.54 ± 2.41 
µM). Furthermore, all three derivatives were cytotoxic to Caco-2 intact cells, with 17 being the least cytotoxic (LC50 = 
151.3 ± 16.3 µM). The xanthone scaffold may be regarded as a pharmacophore for hGSTA1-1 and the three derivatives, 
especially 17, as potent precursors for the synthesis of new inhibitors and conjugate prodrugs for human GSTs.
Keywords: enzyme inhibition, glutathione transferase, multiple drug resistance, xanthone analogue
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cyclophosphamide and other chemotherapeutic drugs have a 
reduced death hazard during the first 5 years following diag-
nosis compared with homozygous hGSTA1*A individuals 
(hazard ratio, 0.3).7 This observation has been attributed to the 
detoxifying role of the isoenzyme hGSTA1 against therapeu-
tic metabolites and/or the therapeutic drug.
Several principles have been proposed for overcoming 
multiple drug resistance (MDR) by GST overexpression, 
employing synthetic drugs and prodrugs as GST inhibi-
tors,8,9 none of which has focused on synthetic xanthone 
analogues. Xanthones have several potential therapeutic 
applications such as antiviral, antimicrobial, anticancer, and 
antioxidant activity.10–12 The antibiotics bicaverin, cervino-
mycins A
1
 and A
2
, psorospermum, lysolypin, and citreami-
cins have a xanthone fragment in their architecture10,11 as 
well as naturally occurring bioactive compounds.13 Their 
planar structure confers DNA intercalation ability upon 
them, and hence expected cytotoxicity, which is considered 
a drawback in their use. Nonetheless, even with these limi-
tations, their selective inhibitory power can still be opti-
mized. An asset is that substituent effects provide important 
information on interaction energies during target binding, 
used in drug design and docking studies.
Many xanthone derivatives bearing methyl, hydroxy, 
methoxy, or phenyl groups or those possessing complex 
polycyclic frameworks have been isolated from families of 
higher plants, fungi, and lichens.10,11,14 Most reports are based 
on derivatives isolated from natural sources, thus hampering 
the availability of the material in sufficient quantity. Indeed, 
studies with xanthones as GST inhibitors have been per-
formed only with compounds of natural origin.15–17 On the 
other hand, the synthesis of analogues from suitably substi-
tuted fragments may be and usually is a multistep process, 
detrimental to the overall yield of the required structure. 
Apparently, being able to introduce functional groups directly 
onto the xanthone pharmacophore scaffold (core structure) 
and perform transformations forthwith would be an approach 
of choice. This concept has been put to the test with a lithia-
tion-electrophilic quench protocol, reported recently.18 The 
emerged reactivity profile has been used in the present inves-
tigation. In fact, to our knowledge, this is the first report on 
well-defined synthetic xanthones as potential inhibitors 
against the human isoenzyme GSTA1-1, known to be 
involved, together with hGSTP1-1, in MDR. Since any struc-
ture-activity relationship (SAR) study begins with the identi-
fication of a lead compound that shows promising inhibitory 
potency for the target enzyme, one may anticipate that xan-
thones identified in the present report as having high inhibi-
tory potency could be exploited as lead structures.
Materials and Methods
The expression plasmid pOXO4-GSTA1 was a much appre-
ciated gift from Prof. C. S. Morrow (Department of 
Biochemistry, Wake Forest University School of Medicine, 
Winston-Salem, NC). The human colon adenocarcinoma 
cell line Caco-2 was obtained from the American Type 
Culture Collection (Manassas, VA). Reagents were used as 
commercially purchased, whereas solvents were purified 
and dried according to standard procedures.
Synthesis of the Xanthone Derivatives
Details on the synthesis of the xanthone derivatives used in 
the present work were described in earlier work.18–20 The 
method followed is summarized in Supplemental Figure S1, 
whereas the derivatives tested and data on reaction condi-
tions and yields are laid out in Supplemental Tables S1  
and S2, respectively. A commentary on the synthesis of the 
xanthone derivatives is presented in the supplementary 
information.
Expression and Purification of Human 
Recombinant Isoenzyme Human GSTA1-1
Human GSTA1-1 (hGSTA1-1) expression and purification 
have been described by Koutsoumpli et al.,21 and a descrip-
tion is also presented in the supplementary information.
Enzyme Assays for Testing the Xanthone 
Derivatives as Inhibitors and Inactivators for 
hGSTA1-1
Enzyme Assay for Determining GSTA1-1 Activity. Determina-
tion of GST activity was performed by monitoring the for-
mation of the conjugate formed between CDNB and the 
tripeptide GSH at 340 nm (ε = 9600 L mol–1 cm–1) at 25 °C. 
A total assay volume of 1 mL contained, typically, potas-
sium phosphate buffer (100 mM, pH 6.5), 1 µmol CDNB 
(33 µL from a 30-mM solution in ethanol), and 2.5 µmol 
GSH (33 µL from a 75-mM aqueous solution). DMSO was 
also added (20 µL, in place of equal volume of buffer) only 
for control assays of inhibition experiments with the xan-
thone derivatives (see below). The mixture was incubated at 
25 °C for 5 min, prior to adding the enzyme sample (20 µL 
purified enzyme or 5 µL Caco-2 cell lysate). Initial veloci-
ties were determined in triplicate and corrected for sponta-
neous reaction rates when necessary. One unit of enzyme 
activity is defined as the amount of enzyme that produces 
1.0 µmol of product per minute at pH 6.5 at 25 °C.
Screening the Xanthone Derivatives as hGSTA1-1 Inhibitors. The 
GST assay described above was used for screening the xan-
thone derivatives (Suppl. Table S1) as possible hGSTA1-1 
inhibitors. Specifically, a total assay volume of 1 mL con-
tained potassium phosphate buffer (100 mM, pH 6.5), 1 µmol 
CDNB (prepared in ethanol), 2.5 µmol GSH (prepared in 
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water), and 100 nmol xanthone derivative (20 µL from a 
5-mM solution in DMSO). The mixture was incubated at 
25 °C for 5 min prior to the addition of the enzyme (20 µL of 
purified enzyme, ~0.18 ΔΑ
340
/min). The observed rate was 
used to calculate the remaining activity (%), taking as 100% 
initial activity value the rate observed after replacing the xan-
thone derivative by an equal volume of DMSO.
Testing the Xanthone Derivatives as GSTA1-1 Inactivators. In a 
volume of 0.904 mL of a potassium phosphate buffer (100 mM, 
pH 6.5), a sample of pure enzyme (10 µL, ~0.09 ΔA340/min) 
and 2 nmol of the xanthone derivative (7, 8, 17; 20 µL from a 
0.1-mM solution in DMSO) were added. The mixture was 
incubated at 25 °C for 30, 60, 120, and 240 s in separate exper-
iments, prior to adding the substrates CDNB (33 µL, 
1 µmol, prepared in ethanol) and GSH (33 µL, 2.5 µmol, pre-
pared in water). The enzyme activity was monitored (340 nm) 
by the formation of the conjugate between CDNB and GSH.
Inhibition Studies with Purified hGSTA1-1 and 
Caco-2 Cell Lysate
Determination of IC
50
 Values for Inhibitors 7, 8, and 17. Ini-
tial velocities for the hGSTA1-1–catalyzed reaction with 
CDNB and GSH as substrates were measured at 25 °C in 
the presence of various concentrations of xanthone deriva-
tives 7, 8, and 17. The reaction mixture contained, in a total 
assay volume of 1 mL, potassium phosphate buffer (100 
M, pH 6.5), 1 µmol CDNB (prepared in ethanol), 2.5 µmol 
GSH (prepared in water), and up to 100 nmol xanthone 
derivative in DMSO (up to 2% in assay mixture). The mix-
ture was incubated at 25 °C for 5 min prior to the addition 
of pure enzyme (20 µL) or cell lysate (5 µL). The observed 
rate was used to calculate the remaining activity (%), tak-
ing as 100% initial activity value the observed rate (~0.15 
ΔΑ340/min and 0.08 ΔΑ340/min for the purified enzyme and 
the cell lysate, respectively) after replacing the xanthone 
derivative by an equal volume of DMSO. The IC50 values 
were determined from a graph depicting remaining GST 
activity (%) versus xanthone derivative concentration.
Kinetic Analysis of Inhibitors 7 and 17 and BSP Using CDNB as 
a Variable Substrate. Initial velocities for the hGSTA1-
1–catalyzed reaction with CDNB as a variable substrate 
were determined in reaction mixtures of a total volume of 1 
mL (25 °C) containing: potassium phosphate buffer (100 
mM, pH 6.5), 2.5 µmol GSH, and different concentrations 
of CDNB (13.5–2100 µM) in the absence and presence of 
inhibitor 7 (1.0, 1.5, and 2.0 µΜ) or inhibitor 17 (0.5, 1.0, and 
2.0 µM) or the control inhibitor BSP (5, 25, and 100 µΜ).
Kinetic Analysis of Inhibitors 7 and 17 Using GSH as a Variable 
Substrate. Initial velocities for the hGSTA1-1–catalyzed 
reaction with GSH as a variable substrate were determined 
in reaction mixtures of a total volume of 1 mL (25 °C): 
potassium phosphate buffer (100 mM, pH 6.5), 1 µmol 
CDNB, and different concentrations of GSH (40–2475 µM) 
in the absence and presence of inhibitor 7 (0.10, 0.25, and 
0.50 µM) or inhibitor 17 (7, 10, and 13 µM).
The GraFit3 computer program (Erithacus Software Ltd, 
Staines, UK) was used throughout for producing kinetic 
graphs and determining apparent kinetic parameters/con-
stants and IC
50
 values.
Caco-2 Cell Line Culture and Preparation of Cell 
Lysate
Cells were grown as monolayer cultures in Dulbecco’s 
modified Eagle’s medium (DMEM) from Biochrom 
(Cambridge, UK) supplemented with 10% v/v fetal bovine 
serum (FBS; GIBCO, Carlsbad, CA), 1% v/v penicillin-
streptomycin solution (GIBCO), and 1% v/v L-glutamine 
(GIBCO). The cells were maintained at 37 °C in an incuba-
tor with 5% CO
2
. For the preparation of stock cell pellet and 
thereafter cell lysate, Caco-2 cells were cultured in 175-cm2 
plastic flasks (Corning, Corning, NY) up to 60% conflu-
ence. To detach cells, the medium was removed from the 
flask, and the cells were washed with 1× phosphate-buff-
ered saline (PBS) and trypsinized with a trypsin/EDTA 
solution (GIBCO) for 2 to 4 min at 37 °C. To inactivate 
trypsin, cells were washed with DMEM containing 10% FBS, 
and the cell clumps were broken through pipetting. 
Subsequently, the cells were washed 5 times with 1× PBS, 
divided in 3 equal portions, and stored as a cell pellet at 
–80 °C. In one of the tubes containing cell pellet, potassium 
phosphate buffer (100 mM, pH 6.5, 500 µL) was added and 
the tube shaken until a suspension formed. The tube was 
then placed in an ice bath and subjected to sonication (3 × 10 s 
with 30-s intervals, 20% amp.) for cell disintegration prior 
to being centrifuged (13,000 rpm, 5 min). The supernatant 
(cell lysate) was collected, tested for GSTA1-1 activity22 
using the assay described earlier (“Enzyme Assay for 
Determining GSTA1-1 Activity”), and used for determina-
tion of IC50 values.
Cytotoxicity Experiments for Determining LC
50
 
Values for Caco-2 Cells with Derivatives 7, 8, 
and 17 and Xanthone
Cytotoxicity was evaluated for Caco-2 cells using the MTT 
assay, which measures the ability of viable cells to reduce a 
soluble tetrazolium salt to an insoluble purple formazan 
precipitate.23 Caco-2 cells used for the MTT assay were 
seeded at a density 1.0 × 104 cells/well in 96-well plates and 
preincubated for 48 h in DMEM containing 10% FBS 
before the addition of xanthone derivatives. These were 
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dissolved in 100% DMSO and then diluted with serum-free 
DMEM as culture medium to different concentrations and 
added to Caco-2 cells cultured in serum-free medium for an 
additional 24 h (the final percentage of DMSO in cultures 
was a limiting factor, especially for derivative 8, in which 
the maximum concentration tested had to be restricted to 
20 µM with up to 2% DMSO in culture). After removal of 
the medium, each well was incubated with 0.5 mg/mL MTT 
(Sigma-Aldrich, St. Louis, MO) in DMEM serum-free 
medium at 37 °C for 3 h. At the end of the incubation period, 
the medium was removed and the intracellular formazan 
was solubilized with 200 µL DMSO and quantified by read-
ing the absorbance at 550 nm on a microplate reader 
(Optimax; Molecular Devices, Sunnyvale, CA). Percentage 
of cell viability was calculated based on the absorbance 
measured relative to the absorbance of cells exposed to the 
negative control.
Modeling and Docking: In Silico Creation of 
the hGSTA1-1 Structure and Docking of the 
Xanthone Derivatives to the hGSTA1-1 Model
The structure of hGSTA1-1 in complex with ethacrynic acid 
and its glutathione conjugate (PDB code 1GSE) was pro-
cessed using MGLTools 1.5.4 (Molecular Graphics 
Laboratory, La Jolla, CA).24 The tripeptide substrate glutathi-
one was added to the protein PDBQT file. Docking of the 
xanthone derivatives to hGSTA1-1 was performed using 
AutoDock 4.0 (Molecular Graphics Laboratory).25 Forty dif-
ferent global molecular properties have been predicted for 
the tested xanthone derivatives using QikProp version 
3.4 (Schrödinger, LLC, New York, NY).26,27 The AutoDock 
free-energy scoring function is based on a linear regression 
analysis, the AMBER force field,28 and a large set of diverse 
protein-ligand complexes with known binding constants. The 
Lamarckian genetic algorithm (LGA) search method with 
default parameters was used. Limits for 5,000,000 maximum 
energy evaluations and 50 docking runs were set. All ligands 
were treated as flexible. Docking results were both visually 
inspected and quantitatively evaluated based on the estimated 
free energy of binding (FEB) values and fitness parameters 
(LE, FQ) for docking to the hGSTA1-1 binding site (Suppl. 
Table S3). All figures depicting 3D models were created 
using PyMOL, version 1.4 (Schrödinger, LLC).
Results and Discussion
Chemistry of the Xanthone Derivatives
Looking at the structure of 1 (Suppl. Table S1), certain fea-
tures are evident: (a) two benzene rings are fused to a 
γ-pyrone ring; (b) the benzene rings, being identical, impart 
symmetrical elements to the structure; (c) the tricyclic 
structure is planar; and (d) the carbonyl group and the ring 
oxygen atom are the major determinants of the reactivity 
profile of 1. The former, as its dimethyl ketal, facilitates 
attack at the peri-positions, through coordination. The lat-
ter, through its lone pair, activates C2 (or C7) as well as its 
peri-positions. During lithiation, there is a competition 
among the lithiated species, the base, and the attacking elec-
trophile. It is not clear whether a prelithiation complex or a 
stabilizing lithium-substrate interaction at the transition 
state is involved.
Monomethylation occurs at C4, whereas dimethylation 
occupies C1/C5 or C4/C5 positions.18 Similarly, iodination 
(not chlorination or bromination) occurs at C1, C4, C1/C5, 
and C4/C5. An aldehyde group is attached solely at C4, but 
an amide group occupies C1, mainly and to a lesser extent 
C4 and both C1/C5 positions.
Radical bromination (NBS/AIBN [or Boc
2
O] in MeCN/
CH
2
Cl
2
) on the C4 methyl group gives the corresponding 
mono-bromomethyl derivative 7 as the major product (in 
42% yield), along with the dibromo-analogue 8 as the minor 
one (in 17% yield). Using the same conditions on the 
4,5-dimethyl derivative 6, all three bromo-products are 
formed (their distribution in the reaction mixture was depen-
dent on the substrate/NBS ratio, the optimum being 2:1, 
whereas the most suitable solvent was MeCN/CH
2
Cl
2
 1:2). 
Using the low solubility of the xanthone core structure, par-
ticularly in nonpolar solvents, to our advantage, the polarity 
of the reaction medium was reduced to favor the desired 
monobromo derivative.
Nuclear bromination of 1, on the other hand, at C2 (or C7) 
or dibromination at those positions can be effected through 
an electrophilic substitution reaction using a large excess of 
Br
2
 in refluxing acetic acid.22 The applied strenuous condi-
tions are needed to overcome the deactivating effect of the 
carbonyl group. Monobromination to 10 is the major reaction 
(in ~74% yield), whereas ~20% of the dibromo derivative 13 
is obtained as a minor product. On the other hand, applying 
Friedel-Crafts conditions (Br
2
/AlCl
3
), the two derivatives are 
obtained in a ~1:1 ratio. Furthermore, C-arylation (mono- 
and diarylation) is affected by Suzuki-Miyaura coupling at 
the brominated sites.19
The planarity and rigidity of 1 lend steady anchoring to 
its complex with hGSTA1-1, whereas its substituent arms, 
at positions C1, C2 (and/or C7), C4, and C5, in derivatives 
4 to 20, steer them through at a preferable conformation and 
binding mode.
Interaction of hGSTA1-1 with the Xanthone 
Derivatives
Prior to proceeding with the inhibition studies, control exper-
iments were implemented with our enzyme preparation using 
BSP as a known hGSTA1-1 inhibitor.29 In silico analysis pre-
dicted that BSP interacts at a noncatalytic binding site, allow-
ing simultaneous binding of the substrate CDNB in the 
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catalytic primary site (Suppl. Fig. S2a). In concert with ear-
lier observations,29 this finding was confirmed by kinetic 
studies, using BSP as an inhibitor and CDNB as a variable 
substrate, demonstrating a noncompetitive modality of inhi-
bition versus CDNB (Suppl. Fig. S2b). Under the same 
experimental conditions, benzylsulfonyl-GSH has shown a 
competitive modality of inhibition.30
Looking at the inhibitory potency values (Suppl. 
Table S1 and Suppl. Fig. S3), certain variations are evi-
dent. Accordingly, at the lower range, methyl groups in 4, 5, 
and 6 appear to have a negligible effect, as does the amide 
in 19 and 20 or the monobromo derivative 10. Values for the 
monoiodo derivatives 14 and 15, on the other hand, are 
doubled, and a similar value is observed for the phenyl ana-
logue 9 and a slightly lower value for the dibromo deriva-
tive 13. Notably higher values are those for 12 and 18. 
Analogues 11 and 16 show a further significant increase, 
whereas 7, 8, and 17 appear to top the list with an impres-
sively high potency. It appears that these observations, 
marking not only actual changes but trends too, point to 
salient features of the substitution pattern and the nature of 
substituents in an aqueous environment, such as hydropho-
bic and H-bonding interactions.31 This is supported by the 
molecular modeling on the active site of hGSTA1-1 and the 
molecular mechanics–driven ligand docking. The low-
energy positions for all derivatives indicate the optimum 
positioning of the ligands in a well-defined hydrophobic 
pocket surrounded by residues Tyr9, Phe10, Leu107, 
Leu108, Pro 110, Val111, Tyr166, Leu213, Phe220, and 
Phe222 (Fig. 1a,b), creating a hydrophobic cage (Fig. 1c,d) 
that can readily accommodate the xanthone derivatives. In 
fact, 40 different global molecular properties have been pre-
dicted for the tested compounds using QikProp version 
3.4.26,27 No strong correlation to potency has been identified 
so far, indicating that a more directional molecular descrip-
tion is required to link potency and structure. In addition to 
mono- and di-substituted compounds that have been syn-
thesized and tested experimentally (Suppl. Table S1), 
88 different structures have been generated and tested in 
silico with substitutions at C2 and C7 positions in addition 
to those at C4 and C5 by adding either or both polar/hydro-
phobic groups. Looking at the FEB values and fitness 
parameters (LE, FQ) for docking to the hGSTA1-1 binding 
site (Suppl. Table S3), it is apparent that all four substitu-
tion positions play an equally important role in the position-
ing of the three-ring structure (xanthone pharmacophore) to 
the binding pocket (Suppl. Fig. S4). Differences between 
di- and tetra-substituted compounds can be predicted as 
high as ~3.5 kcal/mol (Suppl. Table S3), indicating that 
tetra-substituted compounds can be good inhibitors as well. 
However, on the basis of the experimental findings, the 
most important positions appear to be C1, C4, and C5, peri- 
to the O-bearing pyran functionalities, at either mono- or 
di-substitution patterns. Furthermore, C1 is, in general, the 
position giving the highest values. Introduction of a second 
bromine (10 to 13) has a significant increase in inhibitory 
potency, whereas a similar addition of a phenyl group (9 to 12) 
has a weaker effect. In silico modeling has revealed that all 
phenyl substituted analogues at position C7 (9, 11, 12), 
when docked, form a π-π interaction with residue Phe222 
(Fig. 2a). Worth noting, however, is the significant rise of 
11 (42.4% inhibitory potency), indicating the dominance of 
substituent effects operating in concert, such as the hydro-
phobic character and planarity of the phenyl moiety and 
H-bonding with the halogen at a distance of 3.5 Å (11) from 
the guanidinium group of residue Arg13 (Fig. 2a). An ear-
lier report32 endows the Arg residue with an important cata-
lytic role. It appears that either hydrophobic or H-bonding 
interactions would lead to a tighter contact with the enzyme 
binding site, features that, when combined, would lead to a 
further substantial increase of the binding potency. 
Comparing 14 and 15 with 16 strongly suggests the preva-
lence of 1,5–di-substitution (16), at the peri-positions, over 
their mono-substituted variants (14, 15). This is supported 
by the clustering caused during docking where the iodine in 
14 and 15 is placed in a very hydrophobic region, whereas 
in analogue 16, steric constraint forces iodine atoms into 
less hydrophobic positions. The notable increase observed 
in 18, as opposed to its congeners 19 and 20, is not clear. A 
lone pair–peri-repulsive interaction among the pyran car-
bonyl and amide substituent at C1 probably forces the latter 
to assume an out-of-plane orientation and become more 
available to intermolecular interactions with enzyme bind-
ing site. The peri-strain may also cause some ring σ-frame 
distortion. An intramolecular bidentate arrangement of the 
amide substituent at C4 or C5 with the pyran ring O lone 
pair toward a cooperative bonding (e.g., bifurcated 
H-bonding) with an enzyme amino acid residue creates a 
molecular volume not readily accommodated in the 
enzyme’s hydrophobic pocket (Fig. 2b, inhibitor 20), ham-
pering alternative favorable intermolecular interactions. 
Accordingly, the inhibitory potency for 19 and 20, of 
similar magnitude, is low (6.7% and 7.1%, respectively; 
Suppl. Table S1). However, the amide group at C1 in 18, 
apparently through some peri–lone pair interaction with the 
carbonyl oxygen, may cause some ring distortion, facilitat-
ing the positioning of the structure in the enzymatic cavity. 
This may lend support to the measured significantly higher 
inhibitory potency (23.7%; Suppl. Table S1).
Identifying Xanthone “Lead Structures” for 
hGSTA1-1 Inhibitor Design
Derivatives 7, 8, and 17 are by far the most potent inhibitors 
for hGSTA1-1. Furthermore, they do not inactivate the 
enzyme after incubation at different times and in separate 
experiments (2 µM, pH 6.5, and 25 °C); reaction rates 
(ΔA
340
/min) obtained after incubating GST with compound 
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7 for 0, 30, 60, 120, and 240 s were 0.0152, 0.0150, 0.0150, 
0.0153, and 0.0154, respectively.
Derivatives 7 and 8 displayed high inhibitory potency 
(92.6% and 85.5%, respectively; Suppl. Table S1) and low 
IC
50
 values (1.59 ± 0.25 µΜ and 5.30 ± 0.30 µΜ, respec-
tively; Table 1). In silico modeling analysis indicated that 
their low-energy docking positions place the xanthone moi-
ety in the pocket in parallel with the benzene rings of 
Phe220, Phe222, and Tyr9 while the bromine is located 
3.5 Å (7) (Fig. 2c) and 5.1 Å (8) away from the sulfhydryl 
group of GSH and at an even longer distance (4.8 Å for 
7 and 6.5 Å for 8) from the catalytically important Tyr9. This 
behavior is in coherence with the experimentally observed 
kinetic analysis. For example, derivative 7 displayed a 
purely competitive inhibition modality against CDNB as a 
variable substrate, on the basis of the linearity observed for 
both the double-reciprocal graph (Fig. 3a) and its secondary 
plot (Fig. 3b).33 With GSH, as a variable substrate, deriva-
tive 7 has shown a mixed (noncompetitive, α > 1) inhibition 
modality, on the basis of the lines of the double-reciprocal 
plot of initial velocities of hGSTA1-1 versus [GSH] inter-
secting to the left of the reciprocal velocity axis33 (Suppl. 
Fig. S5). This finding suggests binding of 7 at a site differ-
ent from the GSH binding site, with that site being the cata-
lytic CDNB binding site as shown earlier. In conclusion, 
derivative 7 competes with CDNB for the same binding site 
with a kinetically determined inhibition constant Ki(7) = 
0.76 ± 0.18 µΜ. It is worth noting that although synthetic 
Figure 1. Low-energy conformations of the xanthone derivatives and glutathione (GSH) at the primary binding site of hGSTA1-1 
as predicted by in silico molecular docking. All ligands are shown as stick renditions. GSH is depicted in magenta. S atoms are in 
yellow, N atoms in blue, and O atoms in red. Orthogonal views (a) and (b) showing enzyme amino acid residues (in red) forming a 
hydrophobic core around the binding site. Face (c) and side (d) views of the xanthone analogues in the enzyme binding site, which is 
depicted by a color chickenwire representation showing its volume, shape, and the polar characteristics. Green indicates hydrophobic 
regions, whereas red (–) and blue (+) indicate polar ones. The figure is created using the PyMOL program, version 1.5 (Schrödinger, 
LLC, New York, NY).
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xanthone analogues have been reported in the past to affect 
antitumor activity,12,16,34,35 there has been no attempt to cor-
relate experimentally such behavior with the inhibitory 
modality and strength of interaction versus human GST iso-
enzymes involved in MDR.
We have implemented biological assays with the deriva-
tives 7, 8, and 17 using cell lysate derived from human 
colon adenocarcinoma cells (Caco-2 cell line) and intact 
Caco-2 cells. With regard to derivatives 7 and 8, their 
enzyme inhibiting ability has been dramatically decreased 
when using cell lysate compared with purified hGSTA1-1 
(Table 1). In fact, it has not been possible to calculate IC
50
 
values for derivatives 7 and 8 since only ~10% enzyme 
inhibition was observed when approaching their solubility 
limit. This is probably due to interaction of the derivatives 
with various entities of the cell lysate, securing only a small 
Figure 2. Low-energy conformations of four xanthone derivatives at the most probable binding position in the primary site of 
hGSTA1-1, as predicted by in silico molecular docking. All ligands are shown as stick renditions with S atoms in yellow, N atoms in 
blue, O atoms in red, and bromine atoms in brown. (a) Derivative 11 is shown in yellow, and the interaction of its bromine atom 
with the guanidiniun group of Arg13 (3.5 Å) is depicted with a yellow dotted line; the hydrophobic character and planarity of the 
phenyl moiety of 11 operate in concert with the halogen interaction, resulting in a tighter binding with the enzyme. (b) Derivative 20 
occupies only part of the primary binding site of the enzyme depicted with chickenwire representation. Green indicates hydrophobic 
regions, whereas red (–) and blue (+) indicate polar ones. The created molecular volume of 20 is not readily accommodated in the 
enzyme’s hydrophobic pocket. (c) Derivatives 7 and 8 are shown in light brown and beige, respectively, whereas the cosubstrate 
glutathione (GSH) is depicted in magenta. The interaction of the bromine atom of derivative 7 with the sulfhydryl group of GSH 
(3.5 Å) is shown with a yellow dotted line. (d) Derivative 17 occupies part of the primary binding site of the enzyme depicted with a 
chickenwire representation. Green indicates hydrophobic regions, whereas red (–) and blue (+) indicate polar ones. The OH group (in 
red) of derivative 17 forms an H-bond interaction with the backbone carbonyl group of Pro206 (3.2 Å). The interaction is depicted by 
a dotted yellow line. All figures are created using the PyMOL program, version 1.5 (Schrödinger, LLC, New York, NY).
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free amount of the derivative for GST inhibition, indicative 
of low selectivity of 7 and 8 for GST. Furthermore, these 
derivatives functioned as cytotoxic agents with intact 
Caco-2 cells (Suppl. Fig. S6a,b). Especially derivative 
7 showed a substantially lower LC
50
 value (50.2 ± 0.8 µΜ; 
Table 1) compared with plain xanthone (>400 µM; 
Suppl. Fig. S6d). Determination of an LC
50
 value was not 
possible for derivative 8 since the final percentage of 
DMSO in cultures was a limiting factor for the cell viability 
assays (Suppl. Fig. S6b). The derivatives tested were 
totally dissolved in 100% DMSO at different concentra-
tions. Derivative 8 was the least soluble, showing complete 
solubility in DMSO only up to 1 mM. On the other hand, 
derivatives 7 and 17 and plain xanthone were completely 
Table 1. Xanthone Derivatives 7, 8, and 17 as Human GSTA1-1 Inhibitors (IC
50
 Values) and Cytotoxic Agents for Caco-2 Cells 
(LC
50
 Values).
Derivative Code Compound Structure IC
50
LC
50
 
With Purified hGSTA1-1, 
µM
With Caco-2 Cell Lysate, 
µM
With Caco-2 Intact Cells, 
µM
7
O
O
CH
2
BrCH
3
1.59 ± 0.25 ND 50.2 ± 0.8
8
O
O
CH
2
BrCH
2
Br
5.30 ± 0.30 ND >20a
17
O
O
CHO
8.56 ± 0.14 10.54 ± 2.41 151.3 ± 16.3
1 (xanthone)
O
O — — >400
Caco-2, human colon adenocarcinoma cell line; ND, not determined due to low enzyme inhibition at a derivative solubility limit in cell lysate (~10% 
inhibition at 150 µM); —, no enzyme inhibition at 100 µM xanthone.
aFor the cell viability assays, the final percentage of DMSO in cultures was a limiting factor. For compound 8, the maximum concentration tested had to 
be restricted to 20 µM with 2% DMSO in culture.
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Figure 3. Purely competitive inhibition kinetics of hGSTA1-1 with derivative 7 using CDNB as a variable substrate. (a) Lineweaver-
Burk (double-reciprocal) plot of initial velocities of hGSTA1-1 versus [CDNB] (13.5–2100 µM) at different concentrations of 
derivative 7 (0, 1.0, 1.5, and 2.0 µM). (b) Secondary plot derived from data of plot a. The inhibition constant K
i(7)
 for derivative 7 
is the intercept on the inhibitor concentration axis. Points of enzyme velocity are the average of three enzyme assays. The plot is 
created using the GraFit3 program (Erithacus Software Ltd, Staines, UK).
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dissolved in DMSO at 10, 25, and 50 mM, respectively. For 
derivative 8, the maximum concentration tested had to be 
restricted to 20 µM with 2% DMSO in culture.
Turning to derivative 17, its formyl group at C4 has no 
spatial restriction to any orientation of its carbonyl oxygen, 
being free to interact with the enzyme environment. The 
effective binding of derivative 17 to hGSTA1-1 is reflective 
of its high inhibitory potency (86.7%; Suppl. Table S1) and 
low IC
50
 value (8.56 ± 0.14 µΜ; Table 1). Furthermore, 
molecular modeling analysis indicated that 17 can be 
accommodated in the substrate site with the aldehyde group 
positioned in a polar extension pocket formed by the car-
bonyl oxygens of residues Pro206 and Pro207, so as to form 
an H-bond interaction (3.2 Å) with the backbone carbonyl 
group of Pro206 (Fig. 2d). This is in concert with kinetic 
analysis experiments, using CDNB as a variable substrate, 
according to which derivative 17 displayed a purely com-
petitive inhibition modality on the basis of the linearity 
observed for both the double-reciprocal graph (Fig. 4a) and 
its secondary plot (Fig. 4b).33 With GSH as the variable 
substrate, a mixed (noncompetitive, α > 1) inhibition modal-
ity was observed with derivative 17 (Suppl. Fig. S7), as 
with 7 earlier. This behavior suggests that derivative 
17 competes with CDNB for the same binding site, being a 
potent inhibitor for hGSTA1-1 with a kinetically deter-
mined inhibition constant K
i(17)
 = 1.69 ± 0.08 µΜ. The 
enzyme could not accept derivative 17 as a substrate since, 
in this case, the hemithioacetal formed incipiently as the 
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Figure 5. Concentration-response plots for determining IC
50
 values of the xanthone derivative 17 for hGSTA1-1 purified (a) and in 
Caco-2 cell lysate (b). The concentration values (µM) are presented on the logarithmic scale and the response values (as fractional 
activity of inhibited over uninhibited rates) on the glutathione transferase (GST) activity axis.
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Figure 4. Purely competitive inhibition kinetics of hGSTA1-1 with derivative 17 using CDNB as a variable substrate. (a) Lineweaver-
Burk (double-reciprocal) plot of initial velocities of hGSTA1-1 versus [CDNB] (13.5–2100 µM) at different concentrations of 
derivative 17 (0, 0.5, 1.0, and 2.0 µM). (b) Secondary plot derived from data of plot a. The inhibition constant Ki(17) for derivative  
17 is the intercept on the inhibitor concentration axis. Points of enzyme velocity are the average of three enzyme assays. The plot is 
created using the GraFit3 program (Erithacus Software Ltd, Staines, UK).
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cysteine S-conjugate of GSH is clearly transient,36 collaps-
ing back to its individual components.
Testing derivative 17 with GST in the Caco-2 cell lysate, 
its inhibitory ability was similar to that with purified enzyme 
on the basis of the comparable IC
50
 values obtained: 8.56 ± 
0.14 µM with purified hGSTA1-1 (Fig. 5a and Table 1) and 
10.54 ± 2.41 µM with cell lysate (Fig. 5b and Table 1). The 
plateau observed at a high concentrations of derivative 17 
may reflect phenomena of enzyme partial inhibition and/or 
solubility limitation of the inhibitor. It is reasonable to assume 
that the comparable IC
50
 values obtained for the purified and 
cell lysate enzyme suggest some degree of selectivity exhib-
ited by 17 being not particularly prone to interaction with 
entities of the cell lysate, as did derivatives 7 and 8. 
Interestingly, derivative 17 has shown a substantially lower 
cytotoxic effect with intact Caco-2 cells (LC
50(17)
 = 151.3 ± 
16.3 µΜ; Suppl. Fig. S6c and Table 1) compared with deriv-
ative 7 (LC
50(7)
 = 50.2 ± 0.8; Suppl. Fig. S6a and Table 1).
In conclusion, derivatives 7, 8, and 17 have shown a high 
inhibitory potency toward hGSTA1-1, of which derivative 
17 was the only one to readily inhibit the enzyme in colon 
cancer cell lysate. Furthermore, all three derivatives were 
cytotoxic to Caco-2 cells, with 17 being the least cytotoxic. 
Thus, the xanthone scaffold may be regarded as a pharma-
cophore for hGSTA1-1 and the three derivatives, especially 
17, as potent precursors for the synthesis of new inhibitors 
and conjugate prodrugs for human GSTs.30
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